The METTL3-YTHDC1 axis mediates architectural RNA mA modification to modulate the integrity of chromatin TADs in MLLr + AML genome.
1/5 보강
[BACKGROUND] The RNA methyltransferase METTL3 as a key regulator of acute myeloid leukemia (AML) contributes to malignant transformation.
APA
Fu R, Yu W, et al. (2025). The METTL3-YTHDC1 axis mediates architectural RNA mA modification to modulate the integrity of chromatin TADs in MLLr + AML genome.. Molecular cancer, 25(1), 22. https://doi.org/10.1186/s12943-025-02545-x
MLA
Fu R, et al.. "The METTL3-YTHDC1 axis mediates architectural RNA mA modification to modulate the integrity of chromatin TADs in MLLr + AML genome.." Molecular cancer, vol. 25, no. 1, 2025, pp. 22.
PMID
41430607 ↗
Abstract 한글 요약
[BACKGROUND] The RNA methyltransferase METTL3 as a key regulator of acute myeloid leukemia (AML) contributes to malignant transformation. Chromatin topologically associating domains (TADs) are critical for maintaining AML genome integrity, but the mechanism by which METTL3 facilitates TADs integrity in AML progression remains unclear.
[METHODS] To determine whether is transcriptionally activated by MLL in MLL-rearranged (+) AML cells, we analyzed MLL ChIP-seq data. Additionally, we performed a multi-omics approach—including RNA-seq, immunoprecipitation-mass spectrometry (IP-MS) for METTL3 and YTHDC1, DNA: RNA hybrid immunoprecipitation sequencing (DRIP-seq), METTL3 ChIP-seq, CTCF ChIP-seq, H3K4me3 and H3K27ac ChIP-seq—to delineate the functional interplay among METTL3-YTHDC1 axis, R-loops, and CTCF in the + AML genome. Furthermore, METTL3-RIPseq, YTHDC1 RIPseq, CTCF RIPseq, mA-seq, and Hi-C-seq assays were conducted to elucidate the function of the METTL3-YTHDC1 axis-mediated mA modification of architectural RNAs (arcRNAs) in regulating CTCF-dependent TAD boundary activity.
[RESULTS] METTL3 is transcriptionally activated by MLL and forms a complex with YTHDC1 and CTCF, colocalizing at promoters and enhancers in + AML cells. depletion disrupts CTCF binding sites (CBSs) and reduces chromatin accessibility at key leukemic genes (e.g. and ). Hi-C analysis further reveals that YTHDC1 loss compromises CTCF-dependent 3D genome organization. METTL3-mediated mA modification stabilizes arcRNAs and R-loops, which are crucial for maintaining TAD integrity at leukemic loci. Mechanistically, YTHDC1 recognizes mA-modified arcRNAs (e.g. ) to enhance R-loop formation, thereby sustaining CTCF-mediated TAD activity in the + AML genome.
[CONCLUSIONS] Our study identifies the METTL3-YTHDC1-CTCF axis as a critical regulator of AML signature gene expression by orchestrating 3D genome organization. These findings provide novel insights into AML pathogenesis and reveal new therapeutic targets for this kind of aggressive disease.
[GRAPHICAL ABSTRACT] [Image: see text]
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12943-025-02545-x.
[METHODS] To determine whether is transcriptionally activated by MLL in MLL-rearranged (+) AML cells, we analyzed MLL ChIP-seq data. Additionally, we performed a multi-omics approach—including RNA-seq, immunoprecipitation-mass spectrometry (IP-MS) for METTL3 and YTHDC1, DNA: RNA hybrid immunoprecipitation sequencing (DRIP-seq), METTL3 ChIP-seq, CTCF ChIP-seq, H3K4me3 and H3K27ac ChIP-seq—to delineate the functional interplay among METTL3-YTHDC1 axis, R-loops, and CTCF in the + AML genome. Furthermore, METTL3-RIPseq, YTHDC1 RIPseq, CTCF RIPseq, mA-seq, and Hi-C-seq assays were conducted to elucidate the function of the METTL3-YTHDC1 axis-mediated mA modification of architectural RNAs (arcRNAs) in regulating CTCF-dependent TAD boundary activity.
[RESULTS] METTL3 is transcriptionally activated by MLL and forms a complex with YTHDC1 and CTCF, colocalizing at promoters and enhancers in + AML cells. depletion disrupts CTCF binding sites (CBSs) and reduces chromatin accessibility at key leukemic genes (e.g. and ). Hi-C analysis further reveals that YTHDC1 loss compromises CTCF-dependent 3D genome organization. METTL3-mediated mA modification stabilizes arcRNAs and R-loops, which are crucial for maintaining TAD integrity at leukemic loci. Mechanistically, YTHDC1 recognizes mA-modified arcRNAs (e.g. ) to enhance R-loop formation, thereby sustaining CTCF-mediated TAD activity in the + AML genome.
[CONCLUSIONS] Our study identifies the METTL3-YTHDC1-CTCF axis as a critical regulator of AML signature gene expression by orchestrating 3D genome organization. These findings provide novel insights into AML pathogenesis and reveal new therapeutic targets for this kind of aggressive disease.
[GRAPHICAL ABSTRACT] [Image: see text]
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12943-025-02545-x.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (3)
- Artificial Intelligence and Radiomics in Primary Liver Cancer Imaging: A Bibliometric and Visualized Analysis.
- A novel and promising therapeutic approach for treating pancreatic cancer: Nectin‑4‑targeted antibody‑drug conjugates alone or combined with autophagy inhibitors.
- PTC-MAS: A Deep Learning-Based Preoperative Automatic Assessment of Lymph Node Metastasis in Primary Thyroid Cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.
- IDH enzyme inhibition in cancer therapy: mechanisms, mutational insights, and effects of IDH inhibitors in glioma, acute myeloid leukemia and chondrosarcoma.
- Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Induction: The End of Story or Not Yet?
- Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents.
- Reawakening Differentiation Therapy in Acute Myeloid Leukemia: A Comprehensive Review of ATRA-Based Combination Strategies.
- Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.